

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

InVivoPlus anti-mouse NK1.1

RRID:AB_1107737

Type: Antibody

Proper Citation

Bio X Cell Cat# BE0036, RRID:AB_1107737

Antibody Information

URL: http://antibodyregistry.org/AB_1107737

Proper Citation: Bio X Cell Cat# BE0036, RRID:AB_1107737

Target Antigen: NK1.1

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vivo NK cell depletion, Flow cytometry
Consolidation on 12/2021: AB_1107737, AB_2894792.

Antibody Name: InVivoPlus anti-mouse NK1.1

Description: This monoclonal targets NK1.1

Target Organism: mouse

Clone ID: clone PK136

Antibody ID: AB_1107737

Vendor: Bio X Cell

Catalog Number: BE0036

Alternative Catalog Numbers: BE0036-25MG, BE0036-100MG, BE0036-5MG, BP0036-100MG, BP0036-25MG, BE0036-50MG, BP0036-5MG, BP0036-50MG, BE0036-1MG

Record Creation Time: 20250819T231638+0000

Record Last Update: 20250820T045032+0000

Ratings and Alerts

No rating or validation information has been found for InVivoPlus anti-mouse NK1.1.

No alerts have been found for InVivoPlus anti-mouse NK1.1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 102 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Heaton AR, et al. (2026) Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors. bioRxiv : the preprint server for biology.

Xiang H, et al. (2026) Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC. Cell genomics, 6(1), 101062.

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. Cancer immunology research, 14(1), 122.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. Cancer cell, 43(8), 1512.

Garofalo S, et al. (2025) Platelets tune fear memory in mice. Cell reports, 44(2), 115261.

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. Cell reports, 44(6), 115800.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. Cell reports. Medicine, 6(10), 102413.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Wang R, et al. (2025) An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B ?1/2 shedding. Cell reports. Medicine, 6(3), 101981.

Wang Y, et al. (2025) Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. Immunity.

da Silva Bortoleti BT, et al. (2025) A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors.

Nature communications, 16(1), 9915.

Hai Y, et al. (2025) An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma. *Journal of experimental & clinical cancer research* : CR, 44(1), 306.

Jardim C, et al. (2025) Sustained Macrophage Reprogramming Is Required for CD8+ T cell-Dependent Long-Term Tumor Eradication. *Cancer immunology research*, 13(8), 1207.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. *Cell reports. Medicine*, 6(8), 102257.

Yamane K, et al. (2025) ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. *International journal of molecular sciences*, 26(7).

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. *Cell*, 188(24), 6754.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

Lecky DAJ, et al. (2025) Interferon- γ and IL-27 positively regulate type 1 regulatory T cell development during adaptive tolerance. *iScience*, 28(5), 112308.

Kurt-Jones EA, et al. (2025) Interferon-epsilon, an estrogen-induced type I interferon, is uniquely exploited by *Neisseria gonorrhoeae* via effects on sialic acid metabolism. *Cell host & microbe*, 33(7), 1133.